Asenapine pharmacokinetics and tolerability in a pediatric population

References

• PreskornSHClinically important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics: part 1J Psychiatr Pract201218319920422617084
   PubMed Web of Science ®Google Scholar
• CitromeLAsenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolismExpert Opin Drug Metab Toxicol201410689390324793403
   PubMed Web of Science ®Google Scholar
• MauriMCPalettaSMaffiniMClinical pharmacology of atypical antipsychotics: an updateEXCLI J2014131163119126417330
   PubMed Web of Science ®Google Scholar
• MinassianAYoungJWEvaluation of the clinical efficacy of asenapine in schizophreniaExpert Opin Pharmacother201011122107211520642375
   PubMed Web of Science ®Google Scholar
• Saphris [prescribing information]DublinAllergan2017
   Google Scholar
• McintyreRSCohenMZhaoJAlphsLMacekTAPanagidesJA 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed statesBipolar Disord200911767368619839993
   PubMed Web of Science ®Google Scholar
• McintyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trialJ Affect Disord20101221–2273820096936
   PubMed Web of Science ®Google Scholar
• McintyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension studyJ Affect Disord2010126335836520537396
   PubMed Web of Science ®Google Scholar
• KaneJMCohenMZhaoJAlphsLPanagidesJEfficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophreniaJ Clin Psychopharmacol201030210611520520283
   PubMed Web of Science ®Google Scholar
• SzegediACalabreseJRStetLAsenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extensionJ Clin Psychopharmacol2012321465522198448
   PubMed Web of Science ®Google Scholar
• SzegediAZhaoJvan WilligenburgANationsKRMackleMPanagidesJEffects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trialsBMC Psychiatry20111110121689438
   PubMed Web of Science ®Google Scholar
• SchoemakerJStetLVrijlandPNaberDPanagidesJEmsleyRLong-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension studyPharmacopsychiatry201245519620322454251
   PubMed Web of Science ®Google Scholar
• LandbloomRLMackleMWuXAsenapine: efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorderJ Affect Disord201619010311026496015
   PubMed Web of Science ®Google Scholar
• FindlingRLLandbloomRLSzegediAAsenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorderJ Am Acad Child Adolesc Psychiatry201554121032104126598478
   PubMed Web of Science ®Google Scholar
• FindlingRLLandbloomRLMackleMLong-term safety of asenapine in pediatric patients diagnosed with bipolar I disorder: a 50-week open-label, flexible-dose trialPaediatr Drugs201618536737827461426
   PubMed Web of Science ®Google Scholar
• FindlingRLLandbloomRPMackleMSafety and efficacy from an 8 week double-blind trial and a 26 week open-label extension of asenapine in adolescents with schizophreniaJ Child Adolesc Psychopharmacol201525538439626091193
   PubMed Web of Science ®Google Scholar
• CitromeLRole of sublingual asenapine in treatment of schizophreniaNeuropsychiatr Dis Treat2011732533921655346
   PubMed Web of Science ®Google Scholar
• DogteromPTimmerCde GreefRAsenapine safety, tolerability, and pharmacokinetics after single and multiple doses in healthy volunteersClin Pharmacol Drug Dev20121413114327121455
   PubMed Web of Science ®Google Scholar
• LindbomLRibbingJJonssonENPerl-Speaks-NONMEM (PsN): a Perl module for NONMEM related programmingComput Methods Programs Biomed2004752859415212851
   PubMed Web of Science ®Google Scholar
• ProhnMde GreefRChapelSKerbuschTPopulation pharmacokinetics of asenapine in patients with schizophrenia or bipolar disorderEur Neuropsychopharmacol20099Suppl 3S542S543
   Web of Science ®Google Scholar
• StonerSCPaceHAAsenapine: a clinical review of a second-generation antipsychoticClin Ther20123451023104022494521
   PubMed Web of Science ®Google Scholar
• FindlingRLGoldmanRChiuYYPharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disordersClin Ther201537122788279726631428
   PubMed Web of Science ®Google Scholar
• BitonVEdwardsKRMontourisGDTopiramate titration and tolerabilityAnn Pharmacother200135217317911215835
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAPerryCZiconotideCNS Drugs200620433133816599651
   PubMed Web of Science ®Google Scholar
• MattsonRHCognitive, affective, and behavioral side events in adults secondary to antiepileptic drug useRev Neurol Dis20041Suppl 1S10S1716400290
   PubMedGoogle Scholar
• RauckRMaTKerwinRAhdiehHTitration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe painPain Med20089777778518950436
   PubMed Web of Science ®Google Scholar
• GonzalezJMThompsonPMMooreTAReview of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorderPatient Prefer Adherence2011533334121792304
   PubMed Web of Science ®Google Scholar
• DubovskySLFroboseCPhiriPde GreefRPanagidesJShort-term safety and pharmacokinetic profile of asenapine in older patients with psychosisInt J Geriatr Psychiatry201227547248221755540
   PubMed Web of Science ®Google Scholar
• SchoemakerJNaberDVrijlandPPanagidesJEmsleyRLong-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorderPharmacopsychiatry201043413814620205074
   PubMed Web of Science ®Google Scholar
• FindlingRLPathakSEarleyWRLiuSDelbelloMPEfficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trialJ Child Adolesc Psychopharmacol201424632533524956042
   PubMed Web of Science ®Google Scholar
• SikichLHamerRMBashfordRASheitmanBBLiebermanJAA pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trialNeuropsychopharmacology200429113314514583740
   PubMed Web of Science ®Google Scholar
• FindlingRLMcnamaraNKAtypical antipsychotics in the treatment of children and adolescents: clinical applicationsJ Clin Psychiatry200465Suppl 63044
   PubMed Web of Science ®Google Scholar
• KempDEZhaoJCazorlaPWeight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorderJ Clin Psychiatry201475323824524499969
   PubMed Web of Science ®Google Scholar
• Zyprexa [prescribing information]IndianapolisEli Lilly2009
   Google Scholar
• Seroquel [prescribing information]Wilmington (DE)AstraZeneca2009
   Google Scholar
• ChapelSHutmacherMMHaigGExposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongationJ Clin Pharmacol200949111297130819843656
   PubMed Web of Science ®Google Scholar